Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.

Publication Type:

Journal Article

Source:

Clinical chemistry, Volume 54, Issue 12, p.2007-17 (2008)

Keywords:

2008, Adenomatous Polyposis Coli Protein, Aged, Antigens, Neoplasm, Biopsy, DNA Methylation, Genetic Variation, Glutathione S-Transferase pi, Humans, Logistic Models, Male, Middle Aged, Oncogene Proteins, Fusion, Prospective Studies, Prostate-Specific Antigen, Prostatic Neoplasms, Public Health Sciences Division, Receptors, Retinoic Acid, Reverse Transcriptase Polymerase Chain Reaction, Tumor Markers, Biological, Tumor Suppressor Proteins

Abstract:

TMPRSS2:ERG fusions are promising prostate cancer biomarkers. Because they can occur in multiple forms in a single cancer specimen, we developed a quantitative PCR test that detects both type III and type VI TMPRSS2:ERG fusions. The assay is quantified from a standard curve determined with a plasmid-cloned type III TMPRSS2:ERG fusion target.